FDA Advisory Committee Recommends Approval of Endari from Emmaus Life Sciences for the Treatment of Sickle Cell Disease

TORRANCE, Calif., May 24, 2017 - Emmaus Life Sciences Inc. announced today that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of Endari for the treatment of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news